Drug Profile
Research programme: anticancer fusion protein therapeutics - Synergys Biotherapeutics/University of Miami
Alternative Names: Anti-Ang-1/2 Mab; Anti-EGFR-TAP; Anti-HER2-TAP; NKRL fusion therapeutics; SYN002Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Synergys Biotherapeutics; University of Miami
- Class Antineoplastics; Immunoconjugates; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Ovarian cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 02 Jul 2019 Synergys Biotherapeutics receives second SBIR grant from National Cancer Institute for the development of anti-HER2 antibody fusion candidate for the treatment of ovarian cancer